FundingWatcher
Home / Startups / Top biotech startups / Biotech startups in China

Biotech startups in China

Updated 16 Nov 2026

Reset
Biotech startups in China
One-time CSV
  • 1,440 funded companies, 887 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech~china-500a.csv1,440 rows × 18 columns
CompanyCityLast roundAmountDate
EnjosimShanghaiSeries B$30.1M2026-11-02
AusperBioHangzhouSeries C$120.0M2026-08-27
Drug FarmShanghaiSeries D$55.0M2026-07-13
Tianhu TechnologyMinhangSeries A$29.0M2026-07-13
Degron TherapeuticsShanghaiSeries A$40.0M2026-05-14
Weikaier Pharmaceutical TechnologyNanjingSeries C$29.6M2026-06-02
MindRank AIShanghaiSeries B$52.0M2026-07-08
Bowang PharmaceuticalJiadingSeries A$41.0M2023-11-01

8 rows of the CSV in 5 of its 18 columns.

1,440
Startups
$32.0B
Total raised
285
Funded in the last 12 months
$5.5B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 1,440
30 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Huasaiboman Medical Cell Biology Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. Biotech Qingdao Shi Series B $30.0M 2026-11-09 $30.0M ASBV 11 to 50 2019
Tushen Zhihe Tushen Zhihe provides artificial intelligence protein design services. Artificial intelligence Minhang Seed $1.4M 2026-11-09 $1.5M Wuxi Capital, CHENGMEI VENTURES 11 to 50 2023
Enjosim Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. Biotech Shanghai Series B $30.1M 2026-11-02 $30.1M Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital 51 to 100 2021
Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
QL Biopharma QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. Biotech Beijing Series C $44.7M 2026-09-14 $173.7M Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 101 to 250 2018
Medefa Medefa uses synthetic biology to mass-produce novel PHA biomaterials. Biotech Zhuhai Series B $14.9M 2026-09-02 $16.3M Motianshi Touzi, Taiping Innovation 11 to 50 2019
Yuce Biotechnology Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. Biotech Suzhou Series B $7.4M 2026-08-31 $22.4M Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 101 to 250 2019
AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
Hongxin Biology Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. Biotech Shenzhen Series B $14.0M 2026-08-13 $14.0M Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group 11 to 50 2021
Phil Rivers Technology Phil Rivers Technology provides AI solutions for pharmaceutical research and development. Artificial intelligence Beijing Series A $29.6M 2026-08-05 $57.3M Insight Capital 51 to 100 2015
Layerwave Bio Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. Biotech Daxing Series B $13.8M 2026-07-28 $13.8M IDG Capital, Addor Capital, Hotung Venture Capital 51 to 100 2020
Diyingjia Technology Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. Artificial intelligence Beijing Series C $3.0M 2026-07-28 $32.3M IDG Capital, Legend Capital, Microsoft Accelerator 11 to 50 2017
Shengqiang Technology Shengqiang Technology researches, manufactures, and sells high-tech products. Biotech Shenzhen Series C $13.7M 2026-07-26 $13.7M SDIC Venture Capital 101 to 250 2013
Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017
Drug Farm Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. Artificial intelligence Shanghai Series D $55.0M 2026-07-13 $138.0M DT Capital Partners, South China Venture Capital, BVCF +1 101 to 250 2015
Tianhu Technology Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. Artificial intelligence Minhang Series A $29.0M 2026-07-13 $54.2M Qiming Venture Partners, GSR United Capital, 3E Bioventures 11 to 50 2021
MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Shanghai Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
SynMetaBio SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. Biotech Shanghai Series A $14.7M 2026-07-06 $16.1M MiraclePlus, Linear Capital, Danen Capital 11 to 50 2021
Prime Lifescience Prime Lifescience develops a big data platform for life sciences research and analysis. Biotech Hangzhou Series A $14.7M 2026-06-30 $44.5M Qiming Venture Partners, Qiji Investment, Ennovation Ventures 11 to 50 2021
Lingtai Krypton Biotechnology Lingtai Krypton Biotechnology develops lncRNA drugs to treat human diseases. Biotech Shuangliu Series A $13.7M 2026-06-26 $13.7M Legend Capital, Guosheng Capital, Firefly Haoyue 11 to 50 2021
Artivila Therapeutics Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. Artificial intelligence Shenzhen Series A $14.7M 2026-06-23 $53.3M Highlight Capital, Med-Fine Capital, Hike Capital +2 11 to 50 2018
MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022
ThunderBio Innovation ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. Biotech Jiaxing Series B $17.7M 2026-06-15 $34.6M Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi 11 to 50 2018
Weikaier Pharmaceutical Technology Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. Biotech Nanjing Series C $29.6M 2026-06-02 $120.4M SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 501 to 1,000 2010
HemaCell HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. Biotech Suzhou Series B $14.8M 2026-06-02 $62.0M Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation 1 to 10 2021
Vivolight Vivolight conducts medical research and develops intravascular interventional imaging technology. Biotech Nanshanqu Series E $13.9M 2026-06-01 $52.2M CAS Star, TusStar 51 to 100 2012
YolTech Therapeutics YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. Biotech Minhang Series C $73.8M 2026-05-29 $144.9M K2VC, UnityVC, Decheng Capital +1 11 to 50 2021
Full-Life Technologies Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. Biotech Shanghai Series D $109.0M 2026-05-18 $337.3M Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 51 to 100 2021
Bivision Bivision researches and develops targeted radiopharmaceuticals for therapy. Biotech Shanghai Series B $58.8M 2026-05-18 $100.9M Gaorong Capital, Kaitai Capital, Lichen Capital 11 to 50 2021
Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Shanghai Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021

Table 1. Biotech startups in China: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,440.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 CORXEL Pharmaceuticals CORXEL Pharmaceuticals develops medicines for underserved patients. Biotech Shanghai Series D $287.0M 2026-01-22 $451.8M Leaps by Bayer, RTW Investments 51 to 100 2019
2 New Radiomedicine Technology New Radiomedicine Technology supplies medical isotopes in China. Biotech Chengdu Series E $145.4M 2026-04-03 $330.6M Chengdu Science and Technology Venture Capital 101 to 250 2016
3 AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
4 DP Technology DP Technology applies AI to scientific research and industrial R&D challenges worldwide. Artificial intelligence Haidian Series C $113.9M 2025-12-24 $253.7M Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 101 to 250 2018
5 Full-Life Technologies Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. Biotech Shanghai Series D $109.0M 2026-05-18 $337.3M Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 51 to 100 2021
6 D3 Bio D3 Bio develops and registers medicines as a biotechnology company. Biotech Wuxi Shi Series B $108.0M 2025-12-09 $370.0M Matrix Partners China, Boyu Capital, Medicxi 1 to 10 2020
7 Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
8 Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017
9 Zenitar Zenitar conducts drug research and biomedical technology industrialization. Biotech Chengdu Series C $86.0M 2026-01-12 $155.7M Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital 51 to 100 2019
10 MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022

Table 2. Biotech startups in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Qiming Venture Partners Venture capital firm Shanghai, China 17 1% 7 AusperBio, Tianhu Technology, Prime Lifescience
2 Legend Capital Venture capital firm Beijing, China 12 1% 5 Diyingjia Technology, Delova Biotech, Lingtai Krypton Biotechnology
3 Matrix Partners China Venture capital firm Beijing, China 11 1% 3 Alioth, DP Technology, D3 Bio
4 Kaitai Capital Venture capital firm Hangzhou, China 10 1% 2 Bivision, Levinthal
5 BioVenture Venture capital firm Suzhou, China 9 1% 4 AusperBio, Degron Therapeutics, Essentia Biosciences
6 Hillhouse Investment Angel group Singapore 9 1% 5 Etern, UniXell Biotechnology, Dishi Medical
7 CDH Investments Private equity firm Kowloon City, Hong Kong 8 1% 2 HemaCell, UniXell Biotechnology
8 Shenzhen Capital Group Venture capital firm Nanshan, China 7 0% 2 MoleculeMind, MAXVAX
9 Northern Light Venture Capital Venture capital firm Beijing, China 7 0% 1 HemaCell
10 IDG Capital Private equity firm Beijing, China 7 0% 3 Layerwave Bio, Diyingjia Technology, MAXVAX
11 Gaorong Capital Venture capital firm Wangjing, China 7 0% 3 BioGeometry, Bivision, Allink Biotherapeutics
12 CMB International Capital Corporation Investment bank Central, Hong Kong 6 0% 1 HemaCell
13 Lilly Asia Ventures Venture capital firm Shanghai, China 6 0%
14 Puhua Capital Venture capital firm Hangzhou, China 6 0% 1 Yuce Biotechnology
15 SDIC Venture Capital Venture capital firm Xicheng, China 5 0% 2 Shengqiang Technology, Weikaier Pharmaceutical Technology

Table 3. Biotech startups in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 1,203 84% $28.5B
Software 87 6% $3.2B
Artificial intelligence 65 5% $2.3B
Hardware 33 2% $107.5M
Energy 10 1% $885.9M
Cybersecurity 5 0%
Commerce 4 0%
Education 3 0% $2.9M
Fintech 1 0%

Table 4. Biotech startups in China by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Pre-seed 1 0%
Seed 419 29% $1.4M
Series A 485 34% $14.0M
Series B 301 21% $14.9M
Series C 160 11% $29.9M
Series D+ 74 5% $46.9M

Table 5. Biotech startups in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 229 16%
Hangzhou 129 9%
Beijing 124 9%
Suzhou 109 8%
Shenzhen 98 7%
Nanjing 70 5%
Guangzhou 52 4%
Haidian 49 3%
Chengdu 39 3%
Minhang 33 2%
Wuhan 30 2%
Changping 26 2%

Table 6. Biotech startups in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 9 3% $195.9M
October 2026 16 6% $146.6M
September 2026 18 6% $836.5M
August 2026 24 8% $503.4M
July 2026 35 12% $551.0M
June 2026 19 7% $333.2M
May 2026 25 9% $499.4M
April 2026 14 5% $375.2M
March 2026 19 7% $363.2M
February 2026 17 6% $214.8M
January 2026 38 13% $591.2M
December 2025 38 13% $715.9M
November 2025 13 5% $138.6M

Table 7. Biotech startups in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 234 16% $4.6B
2025 222 15% $2.8B
2024 178 12% $1.2B
2023 195 14% $2.3B
2022 147 10% $4.1B
2021 119 8% $4.8B

Table 8. Biotech startups in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 124 9%
2020 to 2022 356 25%
2015 to 2019 513 36%
2010 to 2014 250 18%
Before 2010 172 12%

Table 9. Biotech startups in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 86 8%
11 to 50 454 41%
51 to 100 256 23%
101 to 250 173 15%
251 to 500 71 6%
501 to 1,000 50 4%
1,001 to 5,000 23 2%
5,001 to 10,000 3 0%
10,001 or more 2 0%

Table 10. Biotech startups in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in China are on the list?
1,440, in the file dated 16 November 2026. 285 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 1,440 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups in China: 1,440 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $349 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech startups in China by funding stage

Other sectors in China

Biotech startups elsewhere

Cite: FundingWatcher, 1,440 funded biotech companies in China, 16 November 2026. https://fundingwatcher.com/startups/biotech/china-500a/